ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today provided an update on Cell Cures product development and partnering activities.
On February 16, 2015, Cell Cure opened the clinical trial of OpRegen titled Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients with Advanced Dry-Form Age-Related Macular Degeneration with Geographic Atrophy at Hadassah University Medical Center in Jerusalem, Israel. Patient enrollment is expected to begin shortly. OpRegen consists of animal product-free retinal pigment epithelial (RPE) cells with high purity and potency.
On October 31, 2014, the United States Food and Drug Administration (FDA) cleared Cell Cure's Investigational New Drug (IND) application to initiate the clinical trial of OpRegen in patients with the severe form of age-related macular degeneration (AMD) with geographic atrophy (GA). While treatment options exist for the treatment of the wet form of AMD, it amounts to only about 10% of the disease prevalence. There is currently no FDA-approved therapy for the dry form occurring in approximately 90% of those afflicted with AMD. Cell Cure intends to transplant OpRegen as a single dose into the subretinal space of patients eyes in order to test the safety and efficacy of the product in this leading cause of blindness.
The Phase I/IIa clinical trial, will evaluate three different dose regimens of OpRegen. Following transplantation, the patients will be followed for 12 months at specified intervals, to evaluate the safety and tolerability of the product. Following the initial 12 month period, patients will continue to be monitored at longer intervals for an additional period of time. A secondary objective of the clinical trial will be to examine the ability of transplanted OpRegen to engraft, survive, and moderate disease progression in the patients. In addition to thorough characterization of visual function, a battery of ophthalmic imaging modalities will be used to quantify structural changes and rate of GA expansion.
Cell Cure also announced today that the option granted to Teva Pharmaceutical Industries Ltd. (Teva) under a Research and Exclusive Option Agreement of October 7, 2010 to license-in rights to its OpRegen product has expired without having been exercised by Teva. Cell Cure will therefore be continuing the clinical development of OpRegen on its own and pursuing discussions with other potential strategic partners, including those that have already indicated interest in participating in development and commercialization of the product.
Cell Cure also announced that US patent No. 8,956,866 relating to a proprietary method of manufacturing RPE cells (the active ingredient of OpRegen) is expected to issue on February 17, 2015. This patent combined with other patents and patent applications in the BioTime family of companies provides significant patent protection for this novel therapeutic modality for AMD.
The large markets currently associated with therapies for the wet form of AMD combined with the elegance of RPE replacement therapy for the larger unmet needs associated with the dry form, highlights why Cell Cure has prioritized the development of this product, said Dr. Charles Irving, CEO of Cell Cure. We look forward to initiation of the trials and providing updates in the coming months.
About Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is one of the major diseases of aging and is the leading eye disease responsible for visual impairment of older persons in the US, Europe and Australia. AMD affects the macula, which is the part of the retina responsible for sharp, central vision that is important for facial recognition, reading and driving. There are two forms of AMD. The dry form (dry-AMD) advances slowly and painlessly but may progress to geographic atrophy (GA) in which RPE cells and photoreceptors degenerate and are lost. Once the atrophy involves the fovea (the center of the macula), patients lose their central vision and may develop legal blindness. There are about 1.6 million new cases of dry-AMD in the US annually, and as yet there is no effective treatment for this condition. About 10% of patients with dry-AMD develop wet (or neovascular) AMD, the second main form of this disease, which usually manifests acutely and can lead to severe visual loss in a matter of weeks. Wet-AMD can be treated with currently-marketed VEGF inhibitors. However, such products typically require frequent repeated injections in the eye, and patients often continue to suffer from continued progression of the underlying dry-AMD disease process. Current estimated annual sales of VEGF inhibitors for the treatment of the wet form of AMD are estimated to be in excess of $5 billion worldwide. The root cause of the larger problem of dry-AMD is believed to be the dysfunction of RPE cells. One of the most exciting therapeutic approaches to dry-AMD is the transplantation of healthy, young RPE cells to support and replace the patients old degenerating RPE cells, which may prevent progression of the atrophy as well as the development of wet-AMD. Pluripotent stem cells, such as hESCs, can provide an unlimited source for the derivation of such healthy RPE cells for transplantation.
About OpRegen
Read more:
Cell Cure Neurosciences Ltd. Provides Update on its Product Development and Partnering Activities
- Exercise Helps Heart Disease Patients Live Longer - November 8th, 2009 [November 8th, 2009]
- If You Have A Heart Attack, Dial 911, Don't Drive To The ER - November 8th, 2009 [November 8th, 2009]
- Dried Plums, Tart Cherries, Grapes- What do they have in common? - November 8th, 2009 [November 8th, 2009]
- Vitamin D for Me! - November 8th, 2009 [November 8th, 2009]
- Bangkok Hospital Named Best Global Hospital - November 8th, 2009 [November 8th, 2009]
- 10 Years of Stem Cell Science? Where's the Beef? - November 8th, 2009 [November 8th, 2009]
- Women Underestimate Heart Disease Risks - November 8th, 2009 [November 8th, 2009]
- A Stem Cell First- New Organ Created and Transplanted Using Adult Stem Cells - November 8th, 2009 [November 8th, 2009]
- Stem Cells Injected Directly Into the Heart- Sounds Familiar - November 8th, 2009 [November 8th, 2009]
- Heart Disease and Depression Are Linked - November 8th, 2009 [November 8th, 2009]
- TheraVitae Wishes Everyone A Happy Thanksgiving - November 8th, 2009 [November 8th, 2009]
- VesCell Adult Stem Cells Helping Pulmonary Hypertension - November 8th, 2009 [November 8th, 2009]
- VesCell Adult Stem Cells Help Dilated Cardiomyopathy Patient - November 8th, 2009 [November 8th, 2009]
- Another Dilated Cardiomyopathy Patient Helped by VesCell Adult Stem Cells - November 8th, 2009 [November 8th, 2009]
- Clinical Data of VesCell Used On Heart Disease Patients - November 8th, 2009 [November 8th, 2009]
- Results of Patients Treated with Adult Stem Cells for Heart Disease - November 8th, 2009 [November 8th, 2009]
- Results of Doctor Using VesCell for Heart Disease Published in Medical Journal - November 8th, 2009 [November 8th, 2009]
- Stem Cells from VesCell Help Another Patient With Congestive Heart Failure - November 8th, 2009 [November 8th, 2009]
- VesCell Uses Adult Stem Cells Not Fetal Stem Cells - November 8th, 2009 [November 8th, 2009]
- Dilated Cardiomyopathy Continues Improving After Stem Cell Therapy - November 8th, 2009 [November 8th, 2009]
- American Doctors Form Group to Oppose FDA's Stance On Adult Stem Cells - November 8th, 2009 [November 8th, 2009]
- Adult Stem Cell Pioneer Passes Away - November 8th, 2009 [November 8th, 2009]
- Dilated Cardiomyopathy Patient Celebrates His 1 Year Stem Cell Treatment Anniversary - November 8th, 2009 [November 8th, 2009]
- Vescell Featured In Forbes Magazine! - November 8th, 2009 [November 8th, 2009]
- Adult Stem Cells Repair Damaged Heart Muscle - November 8th, 2009 [November 8th, 2009]
- No Scooter Needed for Schlueter- Heart Disease Patient Back in Gym After Stem Cell Treatment - November 8th, 2009 [November 8th, 2009]
- Stem cells provide second chance - November 8th, 2009 [November 8th, 2009]
- Adult Stem Cell Therapy Scientific Advisory Board - November 8th, 2009 [November 8th, 2009]
- Partner hospitals give Heart Disease treatment with Adult Stem Cell Therapy - November 8th, 2009 [November 8th, 2009]
- Stem Cell Treating Physicians for Heart Disease - Vescell by Theravitae - November 8th, 2009 [November 8th, 2009]
- Heart Disease Treatment FAQs - Adult Stem Cells Treats Heart Disease - November 8th, 2009 [November 8th, 2009]
- Checklist of 12 Must-Ask Questions for Overseas Treatment - November 8th, 2009 [November 8th, 2009]
- Health teaching for patients with heart disease | VesCell adult stem cell therapy - November 8th, 2009 [November 8th, 2009]
- Ethical Debates Adult Stem Cell Research | VesCell adult stem cells treatment - November 8th, 2009 [November 8th, 2009]
- Heart disease and health policy and nurse | VesCell adult stem cells treatment - November 8th, 2009 [November 8th, 2009]
- After Stent Symptoms | VesCell Adult Stem Cell Therapy - November 8th, 2009 [November 8th, 2009]
- What is adult stem cell research | VesCell Adult Stem Cell Therapy - November 8th, 2009 [November 8th, 2009]
- Alternative Medicine for Coronary Artery Disease | VesCell Adult Stem Cell Therapy - November 8th, 2009 [November 8th, 2009]
- Diabetic, Seven Heart Attack Patient Experiences on Adult Stem Cell Treatment - November 8th, 2009 [November 8th, 2009]
- Congestive Heart Failure and Life Expectancy | VesCell Adult Stem Cell Therapy - November 8th, 2009 [November 8th, 2009]
- Chest Pain After Angioplasty with Stent | VesCell adult stem cells treatment - November 8th, 2009 [November 8th, 2009]
- Use of Stem Cells for Heart Repair | VesCell Adult Stem Cell Therapy - November 8th, 2009 [November 8th, 2009]
- Women health heart attack - November 8th, 2009 [November 8th, 2009]
- Health Facts on the Heart | VesCell Adult Stem Cells Treatment - November 8th, 2009 [November 8th, 2009]
- The Process of Stem Cells | VesCell Adult Stem Cells Treatment - November 8th, 2009 [November 8th, 2009]
- Rest Pain Leg | VesCell adult stem cells for peripheral artery disease - November 8th, 2009 [November 8th, 2009]
- Health Supplements Heart Diabetes | VesCell Adult Stem Cells Treatment - November 8th, 2009 [November 8th, 2009]
- Heart Failure Epidemic | VesCell adult stem cells treatment - November 8th, 2009 [November 8th, 2009]
- Heart Muscle Health Aspects | VesCell adult stem cell therapy - November 8th, 2009 [November 8th, 2009]
- adult stem cells | VesCell adult stem cells treatment - November 8th, 2009 [November 8th, 2009]
- Updated article about adult stem cells therapy, VesCell, as featured in Forbes Magazine - November 8th, 2009 [November 8th, 2009]
- Forbes: Vescell Stem Cell Therapy Saves Heart Failure Patient - November 8th, 2009 [November 8th, 2009]
- Foetal Stem Cells Offer Hope for Stroke Victims - November 8th, 2009 [November 8th, 2009]
- Stem cells could spell end for diabetes jabs - November 8th, 2009 [November 8th, 2009]
- Full text answers about stem cell research - November 8th, 2009 [November 8th, 2009]
- Stem Cell Transplant from Umbilical Cord Blood Is The Only Hope for SCID Sufferer - November 8th, 2009 [November 8th, 2009]
- New Studies About Umbilical Cord Blood And Children With Diabetes - November 8th, 2009 [November 8th, 2009]
- Engineered Blood Vessels Function Like Native Tissu - November 8th, 2009 [November 8th, 2009]
- Umbilical Cord Blood Stem Cells Provide Hope for Life Threatening Diseases - November 8th, 2009 [November 8th, 2009]
- Gov. Schwarzenegger Signs SB962 to Create a System to Collect and Store Umbilical Cord Blood - November 8th, 2009 [November 8th, 2009]
- Baby Boy Treated for Cerebral Palsey with His Own Cord Blood Stem Cells - November 8th, 2009 [November 8th, 2009]
- Cord Blood May Preserve Insulin Production in Newly Diagnosed Children With Type 1 Diabetes - November 8th, 2009 [November 8th, 2009]
- A "Holy Grail" Of Healing, CBS Evening News - November 8th, 2009 [November 8th, 2009]
- After Receiving Unusual Stem Cell Transplant, Coppell Toddler Comes Home from Hospital - November 8th, 2009 [November 8th, 2009]
- Stem Cell Hope for Bone Fractures - November 8th, 2009 [November 8th, 2009]
- Cord Blood Stem Cells And Cardiovascular Disease - November 8th, 2009 [November 8th, 2009]
- Creating a Cord-Blood Lifeline - November 8th, 2009 [November 8th, 2009]
- Saving Cord Blood - November 8th, 2009 [November 8th, 2009]
- Stem Cell Implant to the Brain Helps Improve Parkinson's Symptoms: Presented at SIR - November 8th, 2009 [November 8th, 2009]
- Governor Rendell Signs Bill Into Law - November 8th, 2009 [November 8th, 2009]
- Curing Blood Diseases: How Cord Blood Saves Lives - November 8th, 2009 [November 8th, 2009]
- Cord Blood Registry Gains Momentum in First Quarter; Forecasts Strong Enrollment Growth in 2008 - November 8th, 2009 [November 8th, 2009]
- Study findings from University of Florida, Department of Pediatrics provide new insights into cord blood - November 8th, 2009 [November 8th, 2009]
- Cord Blood Can Be Used To Treat Adult Leukemia - November 8th, 2009 [November 8th, 2009]
- Umbilical cord a lifeline for 2 kids - November 8th, 2009 [November 8th, 2009]
- For Stem Cells, a Role on the Battlefield - November 8th, 2009 [November 8th, 2009]
- Cochlear Repair After Transplant Of Human Cord Blood Cells May Make Hearing Restoration Possible - November 8th, 2009 [November 8th, 2009]
- About Stem Cells - November 8th, 2009 [November 8th, 2009]
- Stem cells: Small wonders - November 8th, 2009 [November 8th, 2009]
- Stem Cell Therapy Lessens Damage Caused By Stroke - November 8th, 2009 [November 8th, 2009]